SCHEMBL7790143

SCHEMBL7790143

c1cc(OC2CCCNC2)ccn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 4/20 0.68
CHRNA4 P43681 4/20 0.68
ROCK1 Q13464 8/20 0.65
PRKCZ Q05513 1/20 0.52
ROCK2 O75116 3/20 0.52
KCNH2 Q12809 1/20 0.52
CHUK O15111 2/20 0.51
PRKX P51817 2/20 0.51
DYRK3 O43781 1/20 0.51
MAP4K4 O95819 1/20 0.51
PIM1 P11309 1/20 0.51
PRKACA P17612 1/20 0.51
RPS6KB1 P23443 1/20 0.51
AKT1 P31749 1/20 0.51
CLK2 P49760 1/20 0.51
PRKG2 Q13237 1/20 0.51
DYRK1A Q13627 1/20 0.51
PRKG1 Q13976 1/20 0.51
PKN2 Q16513 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26668737 1.00 CHRNB2 (0.68) CHRNB2CHRNA4ROCK1PRKCZROCK2
SCHEMBL26668743 1.00 CHRNB2 (0.68) CHRNB2CHRNA4ROCK1PRKCZROCK2
Hydrochloric Acid SCHEMBL26599814 0.98 CHRNB2 (0.66) CHRNB2CHRNA4ROCK1PRKCZROCK2
Hydrochloric Acid SCHEMBL15650400 0.98 CHRNB2 (0.66) CHRNB2CHRNA4ROCK1PRKCZROCK2
Hydrochloric Acid SCHEMBL26599582 0.98 CHRNB2 (0.66) CHRNB2CHRNA4ROCK1PRKCZROCK2
Hydrochloric Acid SCHEMBL26599588 0.98 CHRNB2 (0.66) CHRNB2CHRNA4ROCK1PRKCZROCK2
SCHEMBL2264511 0.89 CHRNB2 (0.66) CHRNB2CHRNA4ROCK1PRKCZROCK2
SCHEMBL2266554 0.89 CHRNB2 (0.66) CHRNB2CHRNA4ROCK1PRKCZROCK2
SCHEMBL2110195 0.89 CHRNB2 (0.66) CHRNB2CHRNA4ROCK1PRKCZROCK2
SCHEMBL17593357 0.82 CHRNB2 (0.67) CHRNB2CHRNA4ROCK1ROCK2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2909170-A1 SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2015-08-26 EP disclosed
WO-2014060341-A1 SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2014-04-24 WO disclosed
US-20010014691-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE TARGACEPT, INC. 2001-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010014691-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE PNMT, HNMT, CHRM3 CHRNB2 32/4885CHRNA4 34/4885ROCK1 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.